SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that on August 7, 2007, it filed with the Securities and Exchange Commission (the “SEC”) a resale registration statement on Form S-3 (the “Registration Statement”) that was effective immediately upon filing with the SEC. Amylin filed the Registration Statement to satisfy certain of its obligations under a registration rights agreement that Amylin entered into in connection with its recent private placement of $575 million in aggregate principal amount of 3.0% convertible senior notes due 2014. The Registration Statement, while effective, allows selling securityholders to publicly resell the convertible senior notes and the common stock issuable upon their conversion, subject to certain limitations included in the registration rights agreement and the satisfaction by selling securityholders of the prospectus delivery requirements of the Securities Act of 1933, as amended (the “Securities Act”), in connection with any such resales.
A written prospectus meeting the requirements of Section 10 of the Securities Act may be obtained from Amylin at 9360 Towne Centre Drive, San Diego, California 92121, Attention: General Counsel.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, selling securityholders may only use the resale registration statement for resales of their securities while it remains effective and subject to the satisfaction of certain other conditions.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com.
Amylin Pharmaceuticals, Inc.
CONTACT: Mark G. Foletta, Senior Vice President of Finance and ChiefFinancial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com/
